Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid Tumor Malignancies

    Cancer Categories
    • Breast,Lung
    Karmanos Trial ID
    • 2022-053
    NCT ID
    • NCT05274451
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator
    • Image of Hirva Mamdani , M.D.
      Hirva
      Mamdani, M.D.
      Lung Cancer Screening, Oncology - Medical View Profile

    Objective:

    Primary Objectives:

    • To evaluate the safety and tolerability of LYL797 in patients with relapsed/refractory TNBC and NSCLC
    • To determine the recommended Phase 2 dose (RP2D) of LYL797

    Secondary Objectives:

    • To evaluate the anti-tumor activity of LYL797
    • To evaluate the pharmacokinetics (PK) (eg, expansion and persistence) in peripheral blood (PB) samples of LYL797
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266